Objectives: The purpose of this study was to assess the effect of Yigong-san on anorexia in children by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).Methods: Eleven electronic databases were searched on May 30, 2022 to collect relevant studies. All studies published up to the search date were considered. RCTs reporting the effect of Yigong-san on the treatment of anorexia in children were included. The primary outcome was an improvement in clinical anorexia symptoms after treatment. In this meta-analysis, continuous and binary outcomes were assessed, and the data were presented as the mean difference and risk ratio with their 95% confidence intervals. The risk of bias was assessed using the Cochrane Collaboration’s risk of bias tool.Results: A total of nine studies were included in this systematic review. The treatment group (Yigong-san only or Yigong-san plus conventional treatment) showed a statistically significant effect compared to the control group (conventional treatment only) in total effective rate (Yigong-san only: RR 1.26, 95% CI 1.17, 1.36, I2=0%; Yigong-san plus conventional treatment: RR 1.32, 95% CI 1.18, 1.47, I2=0%), clinical symptoms, some of the anthropometric outcomes, and biological markers related to appetite and growth in children with anorexia. No serious adverse events related to Yigong-san were reported.Conclusions: Yigong-san showed statistically significant effects as a treatment for anorexia in children. However, the number of studies included in the meta-analysis was insufficient, and the herbs contained in the Yigong-san used in the included studies were not standardized. Future research should focus on the implementation of methodologically robust clinical research.

Objective: The purpose of this study is to assess the effectiveness and safety of using <i>Taeksa-tang</i> for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs).Methods: The search was conducted using keywords such as “dyslipidemia”, “hyperlipidemia”, “taeksa tang”, “zexie tang”, and “takusha to” in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane’s risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web.Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (<i>Taeksa-tang</i> or <i>Taeksa-tang-gagam</i>) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008).Conclusion: This study suggests that <i>Taeksa-tang</i> is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.

Objective: This study was conducted to evaluate the effectiveness of the combination therapy of <i>Yukmijihwang-tang</i> and Western medicine on primary glomerulonephritis.Methods: We conducted a search using keywords, such as <i>Yukmijihwang-tang</i> and Liuwei Dihuang, in eight databases (CNKI, CiNii, Pubmed, Embase, Cochrane, Science On, OASIS, RISS). There was no limit to the publication period of the papers. A meta-analysis was conducted and classified according to the outcome measurements, such as the total effective rate (TER), serum creatinine (SCr), and blood urea nitrogen (BUN). Data analysis was performed using the RevMan 5.4.1 software, and Cochrane’s risk of bias (ROB) was used to assess the quality of the papers.Results: A total of 12 randomized control trials were selected. The meta-analysis showed that the treatment group combining <i>Yumijihwang-tang</i> and Western medicine was more efficient than the control group using Western medicine alone (RR: 1.29, CI: 1.20 to 1.39 p=<0.00001). The treatment group also reduced the BUN (MD: -2.40, CI: -2.90 to -1.89, p<0.00001) and Scr (MD: -33.34, CI: -40.85 to -25.82, P<0.00001) more than the control group.Conclusion: This study suggests that the combination therapy of <i>Yukmijihwang-tang</i> with Western medicine is effective in treating primary glomerulonephritis. However, these findings should be interpreted cautiously due to the unknown or high risk of bias in the included trials.

Objective: This study reports the effects of <i>Gyejigeojakyakgachokchilmolyeoyonggol-tang</i> (GCMYT) in a patient with insomnia after COVID-19 vaccination.Methods: GCMYT was used to treat insomnia following vaccination, and symptoms were evaluated using the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), and a visual analog scale (VAS).Results: The patient’s PSQI, ISI, and VAS scores decreased from 21 to 11, from 25 to 13, and from 7 to 3, respectively.Conclusion: GCMYT is an effective treatment for insomnia following COVID-19 vaccination.

Objective: This report describes the case of a patient with essential tremors of the mouth and hands, which were improved by <i>Yeokhan-san</i> treatment.Methods: To relieve the symptoms, Korean medicine treatments, including <i>Yeokhan-san</i>, Ohaeng-Hwa acupuncture, and electronic moxibustion, were performed. To evaluate the effects of the treatments, the visual analog scale and Fahn-Tolosa-Marin clinical rating scale for tremor were used.Results: After the treatment, the patient's clinical symptoms were improved. The visual analog scale score decreased from 10 to 2 for the hand tremor and from 10 to 1 for the mouth tremor. The Fahn-Tolosa-Marin tremor scores decreased from 3 to 1 for both the hand and mouth tremors.Conclusions: The present case suggests that <i>Yeokhan-san</i> and Ohaeng-Hwa acupuncture are effective for the treatment of essential tremor.